| Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript | 08/10 01:46 | seekingalpha.com |
| Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates | 08/08 18:31 | zacks.com |
| Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results | 08/08 16:01 | globenewswire.com |
| Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results | 08/01 16:05 | globenewswire.com |
| Oncternal Therapeutics to Present in JonesTrading Healthcare Summit | 07/11 16:05 | globenewswire.com |
| Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | 05/30 16:05 | globenewswire.com |
| Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript | 05/09 18:34 | seekingalpha.com |
| Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates | 05/09 18:20 | zacks.com |
| Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results | 05/09 16:01 | globenewswire.com |
| All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy | 05/08 13:01 | zacks.com |